An Epidemiological Surveillance Study to Determine the Incidence of ETEC in Children and Infants in Lusaka (ETEC-Surv)

An Epidemiological Surveillance Study to Determine the Incidence of ETEC in Children and Infants in Lusaka.

Diarrhoea is the one of the top five leading causes of death among children below the age of five years, globally. It is estimated that one in ten deaths in children under five is attributed to diarrhoea. Enterotoxigenic E.coli (ETEC) is one of the major causative agents of moderate-to-severe (MSD) diarrhoea among children both globally and in Zambia.

The overall aim of this study is to document the burden of ETEC associated diarrhoea in Zambian children under 3 years of age.

Study Overview

• Status: Completed
• Conditions: Diarrhea Toddlers; Escherichia Coli Diarrhea
• Intervention / Treatment: Other: No intervention will be done

Detailed Description

This study seeks to determine diarrhoea aetiology, calculate the incidence of moderate-to-severe ETEC-associated diarrhea, and describe the frequency of ETEC colonization factors and enterotoxin types in children under 3 years old in Zambia.

These data are required for the design of an anticipated phase 3 trial of the leading ETEC vaccine (ETVAX®) that will be evaluated in Zambia from 2021 onwards.

The following are the research questions that this study seeks to answer:

1. What is the incidence of MSD with confirmed ETEC aetiology in children under three years old in Zambia?
2. What are the prevalent colonization toxins and factors (CFs) in diarrhoeagenic isolates of ETEC infections in children in Zambia?
3. What are the other common pathogens causing diarrhoea in Zambian children?

This prospective, observational, longitudinal study is proposed at five health facilities in Lusaka. The proposed study sites are Chawama, George, Kanyama, Chainda, and Matero Health Facilities. These facilities are located within typical peri-urban settlements of Lusaka and serves communities with a cumulative total population of over 1 million people. The study will be done in two stages beginning with a household census in the study catchment area of the participating health facilities and then followed by the passive diarrhoea surveillance stage. A surveillance system for passive case detection of diarrhoea will be set up at each facility for the 12-months of the project to detect any seasonal variations of disease burden. Prior to commencement, several community sensitization activities will be conducted within the catchment areas of the health facility.

A stool sample will be collected from each participant who presents to the health facility and is eligible for enrollment. All research samples will be collected at the study site and laboratory assays will be performed as per written SOPs and will be a part of the study documentation. All the samples will be processed in Zambia using the Novodiag® platform. The Novodiag® (Mobidiag Ltd, Finland) is a novel multiplex molecular platform that is based on real-time PCR and microarray technology and can identify various gastroenteritis causing bacteria, parasites and viruses as well as carry out antimicrobial resistance gene testing of organisms.

• Study Type: Observational
• Enrollment (Actual): 6828

Contacts and Locations

Study Locations

• Zambia
  • Lusaka, Zambia, 10101
    • Kanyama First Level Hospital
  • Lusaka, Zambia, 10101
    • Chawama first level hospital
  • Lusaka, Zambia, 10101
    • George Clinic
  • Lusaka, Zambia, 10101
    • Matero Clinical Research Site, Chainda South CRS

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 1 year (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

This study is a multi-site longitudinal observation study, to be conducted at Matero First Level Hospital, Chawama First Level Hospital, George Clinic, Kanyama First Level Hospital and Chainda clinic in Lusaka. The facilities are situated in a typical peri-urban settlement area of Lusaka and serves a community with a combined population of about 1 million. We assume that all sites have similar incidence of ETEC diarrhoea, therefore, each of the 5 sites will enroll 1350 children bringing our total sample size for the study to 6,750 participants.

Description

Inclusion Criteria:

• A child < 36 months old at the time of enrolment.
• A child presenting with diarrhoea (i.e. > 3 episodes of looser than normal stools in 24 hours) at a health facility within the study catchment area and in possession of a study ID number.
• Parents of eligible children, able to understand the study information and give informed consent by signature or thumbprint. (NB. illiterate participants will be able to give consent in the presence of an impartial witness)
• Children living within the study catchment area served by each participating health facility and in possession of a study ID number
• The parent/s who is willing to comply with all stipulated study procedures.
• Parents who are willing to allow their child to submit a stool sample for testing.

Exclusion Criteria:

• Children presenting to the health facility without a study ID number
• Any child born after the Census has taken place
• Any child currently participating in the OEV124 study

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

6750 Children <3 years ( 5 sites); A total of 6750 children from the will be identified from the respective health facility catchment area during the Census stage of the study. Each of the 5 health facilities will identify 1350 children under 3 years of age in their respective catchment area. During the Surveillance stage, the participants will be enrolled into the study if and when they present with diarrhoea at the Health facility.

Other: No intervention will be done; No intervention,Only passive surveillance of Diarrhoea cases will be done

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of MSD ETEC diarrhoea in Zambia.	Number of cases of moderate to severe diarrhoea (MSD) with confirmed ETEC aetiology in children under 3 years old in Zambia and the risk factors for ETEC diarrhoea	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Virulence factors of ETEC isolates	The prevalent ETEC virulence factors (LT, STh and STp ) and colonisation factors (CFA/I, CS1, CS2, CS3, CS4, CS5, CS6, CS7, CS8, CS12, CS14, CS17) in diarrhoeagenic isolates of ETEC.	12 months
The common pathogens causing MSD in children less than 3 years	Number of diarrhoea cases due to Shigella, campylobacter coli/jejuni, Clostridium difficile, EAEC, EHEC, EPEC, Salmonella, Vibrio cholerae, Vibrio parahaemolyticus and Yersinia enterocolitica.	12 months
Seasonality of ETEC diarrhoea	The incidence of ETEC positive diarrhoea cases per month for 1 year.	12 months
Antimicrobial resistance pattern of ETEC	AMR pattern for ETEC will be determined by presence or absence of 9 major carbapenemases genes (KPC, NDM, VIM, IMP, OXA-23, OXA-24, OXA-48/181, OXA-51, OXA-58)	12 months

Collaborators and Investigators

• Sponsor: Centre for Infectious Disease Research in Zambia
• Collaborators: Göteborg University; European and Developing Countries Clinical Trials Partnership (EDCTP); Scandinavian Biopharma AB
• Investigators: Principal Investigator: Monde Muyoyeta, MBChB, Centre for Infectious Disease Research in Zambia

Study record dates

Study Major Dates

• Study Start (Actual): October 15, 2020
• Primary Completion (Actual): October 15, 2021
• Study Completion (Actual): October 15, 2021

Study Registration Dates

• First Submitted: February 5, 2021
• First Submitted That Met QC Criteria: April 6, 2021
• First Posted (Actual): April 9, 2021

Study Record Updates

• Last Update Posted (Actual): July 20, 2022
• Last Update Submitted That Met QC Criteria: July 19, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Keywords: Epidemiology; Incidence
• Additional Relevant MeSH Terms: Infections; Signs and Symptoms, Digestive; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Enterobacteriaceae Infections; Diarrhea; Escherichia coli Infections
• Other Study ID Numbers: 1091-2020

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No